1. Academic Validation
  2. Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models

Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models

  • Neuro Oncol. 2024 Sep 10:noae184. doi: 10.1093/neuonc/noae184.
Aurélie Soubéran 1 2 3 Carine Jiguet-Jiglaire 1 4 Soline Toutain 1 2 Philippe Morando 1 2 Nathalie Baeza-Kallee 1 2 Romain Appay 1 4 5 Céline Boucard 5 3 Thomas Graillon 6 Mikael Meyer 6 Kaissar Farah 6 Dominique Figarella-Branger 1 Emeline Tabouret 1 5 3 Aurélie Tchoghandjian 1 2
Affiliations

Affiliations

  • 1 Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team, Marseille, France.
  • 2 Aix-Marseille Univ, Réseau Préclinique et Translationnel de Recherche en Neuro-Oncologie, Plateforme PETRA"TECH", Marseille, France.
  • 3 APHM, CHU Timone, Service de Neurooncologie, Marseille, France.
  • 4 APHM, CHU Timone, Service de Neuropathologie, Marseille, France.
  • 5 Aix-Marseille Univ, Réseau Préclinique et Translationnel de Recherche en Neuro-Oncologie, Plateforme PE"TRANSLA", Marseille, France.
  • 6 APHM, CHU Timone, Service de Neurochirurgie, Marseille, France.
Abstract

Background: generation of patient avatar is critically needed in neuro-oncology for treatment prediction and preclinical therapeutic development. Our objective was to develop a fast, reproducible, low-cost and easy-to-use method of tumoroids generation and analysis, efficient for all types of brain tumors, primary and metastatic.

Methods: tumoroids were generated from 89 patients: 81 primary tumors including 77 gliomas, and 8 brain metastases. Tumoroids morphology, cellular and molecular characteristics were compared with the ones of the parental tumor by using histology, methylome profiling, pTERT mutations and multiplexed spatial immunofluorescences. Their cellular stability overtime was validated by flow cytometry. Therapeutic sensitivity was evaluated and predictive factors of tumoroid generation were analyzed.

Results: All the tumoroids analyzed had similar histological (N=21) and molecular features (N=7) than the parental tumor. Median generation time was 5 days. Success rate was 65 %: it was higher for high grade gliomas and brain metastases versus IDH mutated low grade gliomas. For high-grade gliomas, neither Other clinical, neuro-imaging, histological nor molecular factors were predictive of tumoroid generation success. The cellular organization inside tumoroids analyzed by MACSima revealed territories dedicated to specific cell subtypes. Finally, we showed the correlation between tumoroid and patient treatment responses to radio-chemotherapy and their ability to respond to immunotherapy thanks to a dedicated and reproducible 3D analysis workflow.

Conclusion: patient-derived tumoroid model that we developed offers a robust, user-friendly, low-cost and reproducible preclinical model valuable for therapeutic development of all type of primary or metastatic brain tumors, allowing their integration into forthcoming early-phase clinical trials.

Keywords

brain metastasis; brain tumor; glioma; patient avatar; tumoroid.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12768
    99.80%, CSF-1R Inhibitor